Multimodality therapy of an acquired factor V inhibitor

Yang Xin Fu, Richard Kaufman, Amy E. Rudolph, Steven E. Collum, Morey A. Blinder

Research output: Contribution to journalArticlepeer-review

35 Scopus citations


Acquired inhibitors of factor V are rare causes of clinical bleeding, whose severity ranges from mild to life-threatening. Optimal treatment of patients with factor V inhibitors is uncertain. We report on our successful treatment approach in a patient with spontaneous, life-threatening intracranial bleeding caused by a factor V inhibitor. The patient deteriorated after initial treatment with fresh-frozen plasma and platelet transfusions. He was subsequently treated with a combination of plasma exchange and chemotherapy, which led to complete recovery. Our experience suggests that plasma exchange may be life-saving in cases of severe bleeding caused by factor V inhibitors. The use of plasmapheresis in conjunction with chemotherapy is an efficacious and well-tolerated treatment and should be considered in patients with factor V inhibitors.

Original languageEnglish
Pages (from-to)315-318
Number of pages4
JournalAmerican journal of hematology
Issue number4
StatePublished - Apr 1996


  • Factor V inhibitor
  • Plasma exchange
  • Plasmapheresis


Dive into the research topics of 'Multimodality therapy of an acquired factor V inhibitor'. Together they form a unique fingerprint.

Cite this